The preventive effect of metformin on progression of benign prostate hyperplasia: A nationwide population-based cohort study in Korea.
Metformin, a first-line treatment for type 2 diabetes mellitus (T2DM), has recently been recognized for its pleotropic anti-proliferative, anti-cancer, and anti-aging effects. Contrary to the studies characterizing metformin effects in prostate cancer, little is known about these effects in BPH prog...
Main Authors: | Yehee Hong, Sanghun Lee, Sungho Won |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0219394 |
Similar Items
-
Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: A nationwide population‐based cohort study
by: Yu‐Jui Kuo, et al.
Published: (2019-05-01) -
Nationwide incidence and treatment pattern of benign prostatic hyperplasia in Korea
by: Young Ju Lee, et al.
Published: (2016-11-01) -
Metformin use and long-term risk of benign prostatic hyperplasia: a population-based cohort study
Published: (2020-12-01) -
Analysis of Present Status for Surgery of Benign Prostatic Hyperplasia in Korea Using Nationwide Healthcare System Data
by: Byeong Jo Jeon, et al.
Published: (2019-03-01) -
The Study About Physical Activity for Subjects With Prevention of Benign Prostate Hyperplasia
by: Ho Won Lee, et al.
Published: (2014-09-01)